Dalbavancin

Drug Profile

Dalbavancin

Alternative Names: A-A-1; BI-397; Dalbavancin hydrochloride; Dalvance; MDL-63,397; V-Glycopeptide; VER 001; VGE; Xydalba; Zeven

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Vicuron Pharmaceuticals
  • Developer Cardiome Pharma; Durata Therapeutics; Pfizer
  • Class Antibacterials; Glycopeptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors; Peptidoglycan inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Skin and soft tissue infections
  • Phase II Osteomyelitis
  • Phase I Bacterial infections
  • Preclinical Pneumonia
  • Research Diabetic foot ulcer; Gonorrhoea
  • No development reported Anthrax; Catheter infections

Most Recent Events

  • 03 Mar 2017 Launched for Skin and soft tissue infections in France (IV)
  • 20 Dec 2016 Launched for Skin and soft tissue infections in Germany (IV)
  • 08 Dec 2016 Launched for Skin and soft tissue infections in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top